ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $115,170 | -7.9% | 18,516 | 0.0% | 0.00% | – |
| Q3 2022 | $125,000 | +5.9% | 18,516 | -1.1% | 0.00% | – |
| Q2 2022 | $118,000 | +14.6% | 18,726 | -14.6% | 0.00% | – |
| Q1 2022 | $103,000 | -59.8% | 21,916 | +140.2% | 0.00% | – |
| Q1 2021 | $256,000 | -26.9% | 9,124 | -31.2% | 0.00% | – |
| Q4 2020 | $350,000 | -0.6% | 13,268 | +41.5% | 0.00% | -100.0% |
| Q3 2020 | $352,000 | -96.7% | 9,374 | -95.5% | 0.00% | -95.2% |
| Q2 2020 | $10,806,000 | +67.3% | 210,610 | +3.9% | 0.02% | +40.0% |
| Q1 2020 | $6,460,000 | -44.2% | 202,631 | +5.1% | 0.02% | -25.0% |
| Q4 2019 | $11,570,000 | +951.8% | 192,711 | +542.4% | 0.02% | +900.0% |
| Q3 2019 | $1,100,000 | -56.8% | 30,000 | -45.2% | 0.00% | -60.0% |
| Q2 2019 | $2,545,000 | -48.6% | 54,702 | -55.6% | 0.01% | -44.4% |
| Q1 2019 | $4,952,000 | -55.3% | 123,334 | -48.7% | 0.01% | -55.0% |
| Q4 2018 | $11,067,000 | – | 240,590 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |